NZ614234B2 - Process for the production of a composition containing 5'-ribonucleotides - Google Patents
Process for the production of a composition containing 5'-ribonucleotides Download PDFInfo
- Publication number
- NZ614234B2 NZ614234B2 NZ614234A NZ61423412A NZ614234B2 NZ 614234 B2 NZ614234 B2 NZ 614234B2 NZ 614234 A NZ614234 A NZ 614234A NZ 61423412 A NZ61423412 A NZ 61423412A NZ 614234 B2 NZ614234 B2 NZ 614234B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- rna
- ribonucleotides
- cell wall
- solid
- wall fraction
- Prior art date
Links
- 239000002336 ribonucleotide Substances 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 102
- 210000002421 cell wall Anatomy 0.000 claims abstract description 55
- 239000007788 liquid Substances 0.000 claims abstract description 38
- 238000000926 separation method Methods 0.000 claims abstract description 33
- 108091028664 Ribonucleotide Proteins 0.000 claims abstract description 29
- 239000007787 solid Substances 0.000 claims abstract description 25
- 208000035404 Autolysis Diseases 0.000 claims abstract description 20
- 206010057248 Cell death Diseases 0.000 claims abstract description 20
- 230000028043 self proteolysis Effects 0.000 claims abstract description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 17
- 238000005119 centrifugation Methods 0.000 claims description 9
- 238000005194 fractionation Methods 0.000 claims description 2
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 31
- 230000000813 microbial effect Effects 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 244000005700 microbiome Species 0.000 description 19
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 18
- 239000012138 yeast extract Substances 0.000 description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 13
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 13
- 230000002358 autolytic effect Effects 0.000 description 13
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 11
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 229940041514 candida albicans extract Drugs 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- YLUGBQJQQLZZNL-UHFFFAOYSA-N O.O.O.O.O.O.O.[Na].[Na] Chemical compound O.O.O.O.O.O.O.[Na].[Na] YLUGBQJQQLZZNL-UHFFFAOYSA-N 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- -1 lipds Proteins 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 235000019583 umami taste Nutrition 0.000 description 2
- WTIFIAZWCCBCGE-UHFFFAOYSA-N 2'-GMP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1OP(O)(O)=O WTIFIAZWCCBCGE-UHFFFAOYSA-N 0.000 description 1
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- WTIFIAZWCCBCGE-UUOKFMHZSA-N guanosine 2'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(O)=O WTIFIAZWCCBCGE-UUOKFMHZSA-N 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-L guanosine 3'-monophosphate(2-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-L 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000015090 marinades Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/23—Synthetic spices, flavouring agents or condiments containing nucleotides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
Abstract
Disclosed is a process to produce a composition containing 5’-ribonucleotides comprising: a) Subjecting a yeast to autolysis under conditions at which at least 50% of the RNA remains in a form degradable into 5’-ribonucleotides; b) Subjecting the autolysate to solid/liquid separation and recovering the RNA-containing cell wall fraction and wherein at least 75% of the RNA remains associated with the cell wall fraction; and c) Converting the RNA in the recovered RNA-containing cell wall fraction into 5’- ribonucleotides, whereby the solid/liquid separation in step b) is done at a pH of lower than 3.5 and higher than 1.0. ering the RNA-containing cell wall fraction and wherein at least 75% of the RNA remains associated with the cell wall fraction; and c) Converting the RNA in the recovered RNA-containing cell wall fraction into 5’- ribonucleotides, whereby the solid/liquid separation in step b) is done at a pH of lower than 3.5 and higher than 1.0.
Description
PROCESS FOR THE PRODUCTION OF A COMPOSITION CONTAINING 5’-
RIBONUCLEOTIDES
Field of the invention
The present invention relates to a process to produce a composition containing 5’-
ribonucleotides.
Background of the invention
Compositions comprising 5’-ribonucleotides are previously described for their flavour
enhancing properties. They are capable of enhancing the savoury and delicious taste in
certain types of food. This phenomenon is described as ‘mouthfeel’ or umami.
The 5’-ribonucleotides are derived from RNA, usually from microorganisms such as
yeast. WO2005067734 discloses a process to produce a composition comprising 5'-
ribonucleotides where the process comprises subjecting a microorganism to autolysis under
conditions at which a substantial part of the RNA remains in a form degradable into 5’-
ribonucleotides, then subjecting the autolysate to solid/liquid separation and recovering the
RNA-containing cell wall fraction and finally converting the RNA in the recovered RNA-
containing cell wall fraction into 5’-ribonucleotides.
Autolytic extracts of microorganisms such as autolytic yeast extracts are concentrates
of the soluble materials obtained from the microorganism (e.g. the yeast) after disruption of
the cells and digestion (lysis) of the polymeric material (protein, carbohydrates, lipds, nucleic
acids). The active microbial (e.g. yeast) enzymes released in the medium after cell disruption
contribute to the lysis. These types of extracts are rich in amino acids and generally do not
comprise 5’-ribonucleotides because during the autolytic process the native RNA is
decomposed or modified in a form which is not degradable into 5’-ribonucleotides. In
particular autolytic yeast extracts are used in the food industry as basic taste providers. The
amino acids present in the yeast extract add a bouillon-type, brothy taste to the food.
Hydrolytic extracts of microorganisms, on the other hand, are concentrates of the
soluble materials obtained after disruption of the cells, digestion (lysis) and addition of
proteases and/or peptidases and especially nucleases to the suspension of the
microorganism during lysis. The native microbial enzymes are inactivated prior to the lysis.
During this process, 5’-ribonucleotides of guanine (5’-guanine mono phosphate; 5’-GMP),
uracil (5’-uracil mono phosphate; 5’-UMP), cytosine (5’-cytosine mono phosphate; 5’-CMP)
and adenine (5’-adenine mono phosphate; 5’-AMP) are formed. When adenylic deaminase is
added to the mixture, 5’-AMP is transformed into 5’-inosine mono phosphate (5’-IMP).
Hydrolytic yeast extracts obtained by this method are rich in 5’-ribonucleotides,
especially rich in 5’-GMP and 5’-IMP. Often yeast extracts are also rich in mono sodium
glutamate (MSG). 5’-IMP, 5’-GMP and MSG are previously described for their flavour
enhancing properties. They are capable of enhancing the savoury and delicious taste in
certain types of food. This phenomenon is described as ‘mouthfeel’ or umami. Yeast extracts
rich in 5’-ribonucleotides and, optionally, rich in MSG, are usually added to soups, sauces,
marinades and flavour seasonings. Yeast extracts rich in 5’-ribonucleotides are preferably
produced using yeast strains with a high RNA content and/or by partial extraction of the cell
content.
A problem of the process disclosed in WO2005067734 is that the amount of 5'-
ribonucleotides in the composition is too low and that due to the presence of amino acids and
short peptides and of others yeast components, they are not very suitable for applications
which require cleanliness of taste.
It is an aspect of the present invention to provide a process to produce compositions
rich in 5'-ribonucleotides which are clean in taste, which process is simple and stable, i.e.
which yields a constant high level of 5'-ribonucleotides. It is a further aspect to provide a
process to produce yeast extract with little turbidity.
Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this
specification (including the claims) they are to be interpreted as specifying the presence of
the stated features, integers, steps or components, but not precluding the presence of one or
more other features, integers, steps or components, or group thereof.
The discussion of documents, acts, materials, devices, articles and the like is included
in this specification solely for the purpose of providing a context for the present invention. It is
not suggested or represented that any or all of these matters formed part of the prior art base
or were common general knowledge in the field relevant to the present invention as it existed
before the priority date of each claim of this application.
Detailed description of the invention
In a first aspect the present invention provides a process to produce a composition
containing 5’-ribonucleotides comprising: a) subjecting a microorganism to autolysis under
conditions at which a substantial part of the RNA remains in a form degradable into 5’-
ribonucleotides; b) subjecting the autolysate to solid/liquid separation and recovering the
RNA-containing cell wall fraction and c) converting the RNA in the recovered RNA-containing
- 2a -
cell wall fraction into 5’-ribonucleotides, whereby the solid/liquid separation in step b) is done
at a pH of lower than 5.1 and higher than 1.0.
In another aspect, the present invention provides a process to produce a composition
containing 5’-ribonucleotides comprising: a) subjecting a yeastmicroorganism to autolysis
under conditions at which at least 50%a substantial part of the RNA remains in a form
degradable into 5’-ribonucleotides; b) subjecting the autolysate to solid/liquid separation and
recovering the RNA-containing cell wall fraction and wherein at least 75% of the RNA remains
associated with the cell wall fraction; and c) converting the RNA in the recovered RNA-
containing cell wall fraction into 5’-ribonucleotides, whereby the solid/liquid separation in step
b) is done at a pH of lower than 3.55.1 and higher than 1.0.
With the term “5’-ribonucleotides” it is herewith intended a mixture of 5’-GMP, 5’-
CMP, 5’-UMP and further 5’-AMP and/or 5’-IMP, wherein said 5’-AMP may be either
partially or completely converted into 5’-IMP. The term “5’-ribonucleotide(s)”
encompasses the free 5’-ribonucleotide as well as a salt thereof.
In the context of the present invention autolysis of a microorganism is defined as
a process wherein degradation of the microbial cells and of the polymeric microbial
material is at least partially effected by active native microbial enzymes released in the
medium after (partially) damaging and/or disrupting the microbial cell wall.
Any microorganism can be used as natural source of RNA in the process of the
invention. Bacterial and fungal microorganisms are preferred, such as those which are
suitable for food and feed applications. Preferred microorganisms are those that have
the status of being food-grade and that can be safely applied in food for human
consumption. Bacterial or fungal strains with a high RNA content (i.e. with an RNA
content of typically 6-15%) enable the production of compositions with a high amount of 5’-
ribonucleotides. However an advantage of the process of the invention is that also
bacterial or fungal strains with a relatively low RNA content can be used. These strains
can be advantageously used for the preparation of compositions containing a higher 5’-
ribonucleotide content than would be expected on basis of the RNA content of the
starting strain.
Examples of preferred microorganisms include filamentous fungi such as
Trichoderma or Aspergillus, and yeasts such as Saccharomyces, Kluyveromyces and
Candida. Strains belonging to the genus Saccharomyces, in particular belonging to the
species Saccharomyces cerevisiae are most preferred.
Examples of suitable bacterial microorganisms are lactic acid bacteria, e.g.
Lactobacillus.
The microorganism used in the process of the invention may be prepared by any
suitable fermentation process known in the art. The microbial biomass may be
concentrated prior to its use in the present process, for example by centrifugation or
filtration. For example, cream yeast (baker’s yeast which has been concentrated to a dry
matter content of 15-27% w/w) may be used. Optionally fermentation broths comprising
Brewer’s yeast or residue yeast derived from breweries (spent Brewer’s yeast) may be
used.
The present invention provides a process which is especially suitable for large
scale production of compositions containing 5’-ribonucleotides. Large scale means that
fermentation is performed in fermentors of more than 10 m .
The autolytic process is initiated by damaging and/or partially disrupting the
microbial cell walls. This way the cells are partially opened and at least some of the cell
content is released. In order to damage and/or partially disrupt the microbial cell walls,
the cells are treated chemically, mechanically or enzymatically using methods known to
those skilled in the art.
Mechanical treatments include homogenisation techniques. At this purpose, use
of high-pressure homogenisers is possible. Other homogenisation techniques may
include mixing with particles, e.g. sand and/or glass beads, or the use of a milling
apparatus (e.g. a bead mill).
Chemical treatments include the use of salts, alkali and/or one or more
surfactants or detergents. Chemical treatments are less preferred because they may
lead to partial degradation of RNA especially when alkali is used, with consequent
formation of 2’-ribonucleotides and 3’-ribonucleotides.
The inventors have surprisingly found that the amount of 5'-ribonucleotides in the
composition produced by the process of the invention may be high, e.g. higher than
when the pH in step b) is 5.1 or higher which is very desirable. In contrast, the pH during
the solid/liquid separation step in the process of WO2005067734 is always 5.1.
WO2005067734 does not suggest that when the solid-liquid separation and/or the
recovering of the RNA-containing cell walls may result in an increased amount of 5'-
ribonucleotides.
In an embodiment, the pH during the solid/liquid separation in step b) is lower
than 5.1, preferably 4.5 or less, more preferably 4.2 or less, even more preferably 4.0 or
less, most preferably 3.5 or less1 and higher than 1.0. Preferred pH-ranges are from 1.0
- 5.0 or from 1.0 - 4.5 or from 1.0 - 4.2 or from 1.0 - 3.5 and from 2.0 - 5.1 or from 2.0 -
4.5 or from 2.0 - 4.2. Most preferred is the pH range 2.0 - 3.5.
The solid-liquid separation in step b) is preferably done by common solid-liquid
separation methods, preferably by centrifugation or filtration.
In a preferred embodiment the solid-liquid separation in step b) is done by
centrifugation. Use of centrifugation is economically advantageous, in particular when
the process is performed at large scale.
In the process of the invention the conditions used in the autolytic process are
such that a substantial part of the RNA remains in a form degradable into 5’-
ribonucleotides. In this context, with “substantial part of the RNA” is meant preferably at
least 50%, more preferably at least 60%, 70%, 75%, even more preferably at least 80%,
most preferably at least 83%, al based on the total amount of RNA prior to step b).
Thus, the RNA does not need to remain fully intact during the autolytic process, but at
least a substantial part of the RNA should remain in a form degradable into 5’-
ribonucleotides. Generally up to 100% of the RNA may remain in a form degradable into
’-ribonucleotides. In a form degradable into 5’-ribonucleotides means that the RNA
should be in a form that allows conversion into 5’-ribonucleotides by a suitable enzyme.
Preferably the suitable enzyme is a 5’-phosphodiesterase (5’-Fdase).
A form of RNA degradable into 5’-ribonucleotides comprises oligonucleotides
containing at least two ribonucleotide units. Therefore RNA in a form degradable into 5’-
ribonucleotides may consist of a mixture comprising intact RNA and oligonucleotides or
polynucleotides of different lengths. In the context of the present invention an
oligonucleotide comprises 2-10 ribonucleotide units, while a polynucleotide comprises
more than 10 ribonucleotide units.
The percentage of RNA which remains in a form degradable into 5’-
ribonucleotides during the autolytic process is defined as the ratio (x 100) between a)
the weight percentage of 5’-GMP (calculated as the disodium heptahydrate thereof and
based on sodium chloride free dry matter) measured in the autolysate after inactivation
of the enzymes participating in the autolysis and conversion of RNA into 5’-
ribonucleotides, and b) the weight percentage of GMP (calculated as the disodium
heptahydrate thereof and based on sodium chloride free dry matter) measured in the
starting material after complete alkaline hydrolysis of RNA. The weight percentage of
GMP (calculated as the disodium heptahydrate thereof and based on sodium chloride
free dry matter) measured in the starting material after alkaline hydrolysis can be
determined from the corresponding weight percentage of free GMP (based on sodium
chloride free dry matter) by multiplying the latter with a factor 1.47. The method to
determine the amount of 5’-GMP in the autolysate and of GMP after basic hydrolysis is
described in Example 1. The method used to determine the amount of 5’-GMP can also
be used to determine the amount of 5’-IMP, 5’-AMP, 5’-CMP and 5’-UMP if necessary
with some modifications well within the knowledge of those skilled in the art.
The conditions applied in the autolysis to ensure that a substantial part of the
RNA remains in a form degradable into 5-ribonucleotides will be generally dependent on
the microorganism used.
Preferably damaging and/or partially disrupting the microbial cell wall is done
enzymatically because a better control of the process can thereby be achieved and
because this method is especially suitable to be used at large scale. Several enzyme
preparations can be used like cellulases, glucanases, hemicellulases, chitinases,
proteases and/or pectinases. Preferably protease is used, more preferably
endoprotease is used. The conditions used to initiate the autolytic process are
dependent on the type of enzyme used and can be easily determined by those skilled in
the art. Generally the conditions used to enzymatically damage and/or disrupt the
microbial cell wall will correspond to those applied during the autolysis of the
microorganism.
The autolysis of the microorganism is at least partially effected by active native
microbial enzymes released in solution after (partially) damaging and/or disrupting the
microbial cell wall wherein the chemicals, or more preferably, the enzymes added to
damage and/or to disrupt the microbial cell wall may contribute to the degradation of the
microbial cells and of polymeric microbial material.
In particular the first phase of autolysis is performed at a particular pH range
combined with a particular temperature.
For instance, the conditions applied in the autolysis of Saccharomyces cerevisiae
to ensure that a substantial part of the RNA remains in a form degradable into 5’-
ribonucleotides are such that the pH in the first phase of the autolysis is between 4.5-9
and/or the temperature is between 50-65 C. Preferably the first 8 hours of the autolysis,
more preferably the first 4 hours of the autolysis, are performed at a pH of 4.5-5.5 and at
a temperature of 57-65 C, or at a pH 5.5-9 and a temperature of 50-65 C.
The autolysis conditions to be kept after the first phase are less critical. After the
first phase the pH is generally kept between 4 and 10 and the temperature is generally
kept between 40 C and 70 C. In general the duration of the autolytic process including
the first phase is at most 24 hours.
The present invention may encompass as well a process wherein in step a) a
microorganism is subjected to hydrolysis under conditions at which a substantial part of
the RNA remains in a form degradable into 5’-ribonucleotides. In the context of the
present invention “hydrolysis of a microorganism” is defined as a process wherein the
native microbial enzymes have been inactivated and wherein suitable exogenous
enzymes added to the microbial biomass to effect degradation of the microbial cells and
of the polymeric microbial material.
After autolysis a suspension (autolysate) is obtained which comprises a microbial
cell wall fraction, RNA which is for a substantial part in a form degradable into 5’-
ribonucleotides, and soluble cell components (e.g. proteins, peptides, amino acids,
carbohydrates, etceteras). The cell wall fraction comprises insoluble cell residues, in
particular cell walls or fragments thereof.
At the end of the autolytic process and prior to step b), the chemicals used for
damaging and/or partially disrupting the microbial cell walls and/or the enzymes which
took part in the autolytic process should preferably be neutralised and/or inactivated.
The enzymes which took part in the autolysis are the native microbial enzymes and
optionally any added exogenous enzyme used to initiate the autolytic process.
Neutralisation and/or inactivation of the chemicals and/or the enzymes should occur
under conditions at which a substantial part of the RNA remains in a form degradable
into 5’-ribonucleotides. Inactivation of the enzymes which took part in the autolysis can
be done by pH treatment or preferably by a heat treatment whereby the enzymes are
inactivated, a substantial part of the RNA remains in a form degradable into 5’-
ribonucleotides. The enzymes can be inactivated by heat treatment, for instance by
heating the mixture from 5 minutes to 1 hour at a temperature from 65 C to 95 C, more
preferably by heating from 30 minutes to 1 hour at a temperature from 65 C to 75 C,
wherein typically a shorter reaction time may be used at higher reaction temperatures.
For example, heating the mixture for 1 hour at 65 C, or for 30 minutes at 75 C may be
sufficient to inactivate the enzymes whereby a substantial part of the RNA remains in a
form degradable into 5’-ribonucleotides.
In step b) of the process of the invention the autolysate is subjected to
solid/liquid separation and the RNA-containing cell wall fraction is recovered, wherein
the pH during this is lower than 5.1, preferably 4.5 or less, more preferably 4.2 or less,
even more preferably 4.0 or less, most preferably 3.5 or less1 and higher than 1.0.
Preferred pH-ranges are from 1.0 - 5.0 or from 1.0 - 4.5 or from 1.0 - 4.2 or from 1.0 -
3.5 and from 2.0 - 5.1 or from 2.0 - 4.5 or from 2.0 - 4.2. Most preferred is the pH range
2.0 - 3.5.
The inventors have surprisingly found that a substantial part of the total RNA
remains associated with the recovered cell wall fraction obtained after step b) of the
process of the invention. In an embodiment, in step b) at least 55%, more preferably at
least 75%, most preferably at least 90% of the total RNA remains associated with the
cell wall fraction. Example 2 demonstrates that up to 94.7% of the total RNA in the
autolysate remains associated with the cell wall fraction. It is also demonstrated in
Example 2 that the percentage RNA bound to the yeast cell walls and the turbidity of the
yeast extract are a function of the pH during the solid/liquid separation: at lower pH
values, more RNA remains bound to the cell walls and the turbidity of the yeast extract is
decreasing.
The total amount of RNA (i.e. prior to step b) can be determined by analyzing the
autolysate obtained in step a). A method to analyze RNA is described in Example 1.
The percentage of the RNA which remains associated with the cell wall fraction
is defined as the ratio (x100) between a) the amount of RNA in grams in the cell wall
fraction of an autolysate originating from a fixed amount of starting material, and b) the
amount of RNA in grams present in the same fixed amount of starting material. The
method to determine the amount of RNA in the cell wall fraction and in the starting
material is described in example 1. Preferably the starting material may be the
autolysate obtained after step a) of the process of the invention.
In order to increase the amount of recovered RNA in a form degradable into 5’-
ribonucleotides, the autolysate may be subjected to ultra filtration (UF) instead of to a
common solid-liquid separation method like centrifugation or filtration. In this way, a
mixture of the RNA-containing cell wall fraction and RNA derived from the microbial
soluble fraction is recovered. Thus, not only the RNA associated with the cell wall
fraction is separated from the microbial soluble fraction but also the RNA which had
been released into solution during autolysis. In cases where UF is used to recover RNA,
preferably membranes with a molecular weight cut off from 10 to 50 kDa or preferably
from 20 to 50 kDa can be used. In general a larger molecular weight cut off allows a
higher flow rate through the membrane, but might result in larger losses and/or less pure
products. The type of solid-liquid separation used and the efficiency of said solid-liquid
separation can influence, among other factors, the amount of 5’-ribonucleotides
obtained in the compositions of the invention.
In step b) the RNA-containing cell wall fraction is recovered and the liquid
fraction may be discarded. However, in the process of the invention it is also possible to
recover both the RNA containing cell wall fraction as well as the liquid fraction. Said
liquid fraction may actually be a yeast extract. Not only is this a very economical, but
said yeast extract obtainable by the process of the invention by recovering the liquid
fraction in step b) may be characterized in that it has a low turbidity, which makes it very
suitable to be used in those applications where clarity is important, such as clear soups
and drinks.
In step c) the RNA in the recovered cell wall fraction is converted into 5’-
ribonucleotides. This is preferably done by enzymatically treating the RNA-containing
cell wall fraction, optionally mixed with RNA derived from the microbial soluble fraction
obtained by ultrafiltration.
’-Phosphodiesterase (5’-Fdase) is preferably used to convert RNA into 5’-
ribonucleotides. 5’-phosphodiesterase can be obtained from a microbial or a vegetable
source (for example a malt root extract). An example of a commercially available
microbial 5’-Fdase is Enzyme RP-1 produced by Amano (Japan).
Optionally, 5’-AMP is converted to 5’-IMP by a deaminase, for example adenyl
deaminase. An example of a commercially available deaminase is Deaminase 500
produced by Amano (Japan).
Treatment of RNA by 5’-Fdase and deaminase can be performed in a two-step
or in a single step process.
In a preferred embodiment, the process of the invention comprises after step c)
d) subjecting the 5'-ribonucleotides to a solid-liquid fractionation and recovering
the 5’-ribonucleotides, preferably by separating the 5'-ribonucleotides from the cell wall
fraction, for instance by centrifugation or filtration or by any other method suitable to
achieve solid/liquid separation. This allows to obtain a composition having a very high
amount of 5'-ribonucleotides, e.g. up to 90% w/w, 95% w/w, or even 98% w/w or 99%
w/w, all based on total dry matter.
In an embodiment, the 5’-ribonucleotides are purified by separating said 5'-
ribonucleotides from components having a higher molecular weight than the 5’-
ribonucleotides by ultrafiltration. The degree of purification will depend on the molecular
weight cut-off of the ultrafiltration membrane used. For instance, ultrafiltration
membranes as mentioned above can be used.
It will be understood that in the context of the present invention a wording like
“recovering the RNA” or “converting the RNA" does not necessarily mean that all RNA is
recovered or converted, respectively. It will be clear to those skilled in the art that the
amount of the RNA which is recovered will depend on the type of separation method
used. It will also be clear that the amount of RNA which is converted will depend on
several factors, one of which is the accessibility of the RNA associated with the cell wall
insoluble fraction to the enzymes used in this step.
The process of the invention has several benefits. It allows for the production of
a very pure 5'-ribonucleotides composition. Because it may comprise only 2 steps, it is
very simple. In addition, it may also allow for the production of a yeast extract having a
low turbidity. In this way, both a very clear yeast extract may be produced in addition to
a cell wall fraction rich in RNA and/or a cell wall fraction rich in 5'-ribonucleotides and/or
a very pure 5'-ribonucleotides fraction.
The invention will now be illustrated by some examples which however do not
intend to be limiting.
EXAMPLES
Example 1
Preparation of a composition comprising 5’-ribonucleotides
Two litres of cream yeast from Saccharomyces cerevisiae were heated to 60 C.
Subsequently 0.5 ml Alcalase (commercially available serine protease from Novozymes,
Denmark) was added and the mixture was incubated for 4 hours at pH 6.0 and 60 C.
The conditions were adjusted to pH 5.1 and 51.5 C and an additional 2 ml of Alcalase
was added to the reaction mixture. The mixture was incubated for 20 hours at pH 5.1,
51.5 C. Next, the mixture or autolysate was heated for 1 hour at 65 C to inactivate all
enzyme activity.
The RNA content of the autolysate was 8.7% w/w based on total dry matter. One
part of the autolysate was treated with 5’-phosphodiesterase which resulted in an
amount of 5’-GMP of 2.65% w/w, expressed as disodium heptahydrate and based on
sodium chloride free dry matter. It follows that the fraction of RNA which was degradable
into 5'-ribonucleotides was 83% (w/w).
The other part of the autolysate was subjected to a first solid/liquid separation by
way of centrifugation at a pH of either 5.1 (comparative experiment), 4.2 (experiment 1),
or 3.5 (experiment 2). The cell wall fractions were collected without further pH
adjustment and washed two times with water and analyzed for RNA content. The clear
extract (as the supernatant) was adjusted to a dry matter content of either 13% or 2.5%
by adding water and was subsequently analyzed for turbidity.
The cell wall fractions were further treated 5’-phosphodiesterase at a
temperature of 65 C and a pH of 5.3. Next, 5’-AMP was converted by the enzyme
deaminase into 5’-IMP at a temperature of 55 C and at pH 5.1. After both the 5’-
phosphodiesterase and the deaminase treatment the cell wall fraction was subjected to
a second solid/liquid separation by means of centrifugation and the clear fraction was
analysed for 5'-ribonucleotide content.
Some samples were also incubated with 5’-Fdase in order to establish whether
the RNA present in the samples could be converted into 5’-ribonucleotides (i.e. whether
the RNA was in a form degradable into 5’-ribonucleotides by e.g. 5’-Fdase) and some of
these samples were also treated with deaminase to convert the 5’-AMP into 5’-IMP. The
amount of 5’-GMP, 5’-AMP and 5’-IMP in the samples (expressed as weight percentage
of the disodium heptahydrate thereof based on sodium chloride free dry matter) were
subsequently determined by means of HPLC according to the following method. 5’-
GMP, 5’-AMP and 5’-IMP in yeast extracts were quantified by HPLC using a Whatman
Partisil 10-SAX column, a phosphate buffer pH 3.35 as eluent and UV detection.
Concentrations were calculated on basis of 5’-GMP, 5’-IMP and 5’-AMP standards.
Sodium chloride was determined by measuring the chloride ions in the sample with a
Jenway chloride meter PCLM 3 (Jenway, Essex, England) and calculating the
corresponding amount of sodium chloride.
Table 1. Results of Example 1
pH during the first solid/liquid separation 5.1 4.2 3.5
RNA content of the cell wall fraction (% w/w based on dry matter) 15.2 16.7 19.9
’-GMP content (% w/w) after the phosphodiesterase treatment
.3 5.7 6.6
and before the second solid/liquid separation
% of the RNA in the cell wall fraction 55 75 90
’-GMP content in the clear fraction (% w/w)
obtained after the second solid/liquid separation (5’- 18.6 22.4 25.5
phosphodiesterase treatment only)
’-GMP content in the clear fraction (% w/w) obtained after the
second solid/liquid separation (5’-phosphodiesterase and 19.6 22.7 24.9
subsequent deaminase treatment)
’-IMP content in the clear fraction (% w/w)
obtained after the second solid/liquid separation 20.2 23.1 25.3
(5’-phosphodiesterase and subsequent deaminase treatment)
Turbidity of the clear extract obtained after the first solid/liquid
298 49 31
separation (NTU at 13% dry matter)
Turbidity of the clear extract obtained after the first solid/liquid
57 9.4 6.0
separation (NTU at 2.5% dry matter)
RNA was analyzed as follows: RNA was hydrolysed during an alkaline treatment.
GMP (i.e. 2'-GMP and 3'-GMP derived from the hydrolysis of RNA) was quantified by
means of HPLC, using 5’-GMP as a standard, using a Whatman Partisil 10-SAX
column, a phosphate buffer at pH 3.35 as eluent and UV detection. The weight
percentage of RNA content based on sodium chloride free dry matter corresponds to ~4
times the weight percentage of free GMP based on sodium chloride free dry matter.
Comparative
Example A
Experiment 1
Experiment 2
NTU (turbidity) was determined by nephelometry with a HACH 2100 N turbidity
meter (Hach-Lange, Düsseldorf, Germany) equipped with a tungsten lamp (400-600 nm)
at a temperature of 20°C.
NTU means Nephelometric Turbidity Unit and is measured with the HACH 2100
N turbidity meter. The method is based on light scattering while measuring the scattered
light at an angle of 90 and using formazin solutions as a standard.
Example 2
RNA-partitioning over cell walls and supernatant as a function of pH
The experiments of Example 1 were repeated at pH values ranging from 2.0 to 5.01. All
conditions were identical except that the clear extract (the supernatant) was adjusted to
a dry matter content of 5% by adding water before being analyzed for turbidity. Also,
RNA in the cell wall fractions was not digested by 5’-Fdase.
Table 2. Results of Example 2
pH during the first solid/liquid
2.01 2.49 2.90 3.29 3.49 3.99 4.50 5.01
separation
% of the RNA in the cell wall fraction* 94.6 94.7 94.1 89.4 79.8 59.5 55.3 53.8
% of the RNA in the supernatant* 5.4 5.3 5.9 10.6 20.2 40.5 44.7 46.2
Turbidity of the supernatant (NTU at
6.0 5.3 6.1 3.8 6.0 19.2 34.8 32.9
% dry matter)
* the sum of the RNA in the cell walls and the supernatant is 100% by definition
Experiment 3
Experiment 4
Experiment 5
Experiment 6
Experiment 7
Experiment 8
Experiment 9
Experiment 10
Claims (6)
1. Process to produce a composition containing 5’-ribonucleotides comprising: 5 a) subjecting a yeast to autolysis under conditions at which at least 50% of the RNA remains in a form degradable into 5’-ribonucleotides; b) subjecting the autolysate to solid/liquid separation and recovering the RNA-containing cell wall fraction and wherein at least 75% of the RNA remains associated with the cell wall fraction; and 10 c) converting the RNA in the recovered RNA-containing cell wall fraction into 5’- ribonucleotides, whereby the solid/liquid separation in step b) is done at a pH of lower than 3.5 and higher than 1.0. 15
2. Process according to claim 1 wherein the pH is higher than 2.0.
3. Process according to claim 1 or claim 2 wherein the recovering in step b) is done by centrifugation. 20
4. Process according to any one of claims 1 to 3 comprising after step c) d) subjecting the 5'-ribonucleotides to a solid-liquid fractionation and recovering the 5’- ribonucleotides.
5. A composition prepared by the process of any one of claims 1 to 4.
6. Process according to claim 1, substantially as hereinbefore described, with reference to the examples.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161443900P | 2011-02-17 | 2011-02-17 | |
EP11154867.3 | 2011-02-17 | ||
EP11154867 | 2011-02-17 | ||
US61/443,900 | 2011-02-17 | ||
PCT/EP2012/052545 WO2012110533A1 (en) | 2011-02-17 | 2012-02-15 | Process for the production of a composition containing 5'-ribonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614234A NZ614234A (en) | 2014-09-26 |
NZ614234B2 true NZ614234B2 (en) | 2015-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2513590C (en) | Production of 5'-ribonucleotides | |
CA2549316C (en) | Process for the production of a composition containing 5'-ribonucleotides and compositions thereof | |
US9115379B2 (en) | Process for the production of a composition containing 5′-ribonucleotides | |
US9192184B2 (en) | Process for the production of yeast extracts having low turbidity | |
EP4095252A1 (en) | Process for the production of a composition containing 5' -ribonucleotides | |
JP2014079179A (en) | Seasoning derived from yeast protein | |
NZ614234B2 (en) | Process for the production of a composition containing 5'-ribonucleotides | |
JP2022074430A (en) | Non-acidic amino acid-containing yeast seasoning | |
NZ614235B2 (en) | Process for the production of yeast extracts having low turbidity |